1. Silencing of lysyl oxidase‑like 2 inhibits the migration, invasion and epithelial‑to‑mesenchymal transition of renal cell carcinoma cells through the Src/FAK signaling pathway
   Xi Hong et al, 2019, International Journal of Oncology CrossRef
2. Lysyl oxidase like 2 is increased in asthma and contributes to asthmatic airway remodelling
   Jopeth Ramis et al, 2022, European Respiratory Journal CrossRef
3. Inhibition of LOXL2 and Other Lysyl Oxidase (Like) Enzymes: Intervention at the Core of Fibrotic Pathology
   Alison Findlay et al, 2020, Anti-fibrotic Drug Discovery CrossRef
4. Lysyl oxidase inhibitors attenuate cyclosporin A-induced nephropathy in mouse
   Long T. Nguyen et al, 2021, Scientific Reports CrossRef
5. Lysyl oxidase like-2 in fibrosis and cardiovascular disease
   Alan Poe et al, 2023, American Journal of Physiology-Cell Physiology CrossRef
6. LOXL2, a copper-dependent monoamine oxidase, activates lung fibroblasts through the TGF-β/Smad pathway
   Xiaohong Wen et al, 2018, International Journal of Molecular Medicine CrossRef
7. Fibrosis in Mesothelioma: Potential Role of Lysyl Oxidases
   Lara Perryman et al, 2022, Cancers CrossRef
8. Chemokine Therapy in Cats With Experimental Renal Fibrosis and in a Kidney Disease Pilot Study
   Julie Bennington et al, 2021, Frontiers in Veterinary Science CrossRef
9. The lysyl oxidase like 2/3 enzymatic inhibitor, PXS‐5153A, reduces crosslinks and ameliorates fibrosis
   Heidi Schilter et al, 2019, Journal of Cellular and Molecular Medicine CrossRef
10. Lysyl oxidase like-2 contributes to renal fibrosis in Col4α3/Alport mice
    Dominic Cosgrove et al, 2018, Kidney International CrossRef